DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Temovate (Clobetasol Propionate Topical) - Summary

 
 



TEMOVATE SUMMARY

TEMOVATE (clobetasol propionate emollient cream)
Emollient, 0.05%

TEMOVATE (clobetasol propionate cream and ointment) Cream and Ointment contain the active compound clobetasol propionate, a synthetic corticosteroid, for topical dermatologic use. Clobetasol, an analog of prednisolone, has a high degree of glucocorticoid activity and a slight degree of mineralocorticoid activity.

TEMOVATE Cream and Ointment are super-high potency corticosteroid formulations indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Treatment beyond 2 consecutive weeks is not recommended, and the total dosage should not exceed 50 g/week because of the potential for the drug to suppress the hypothalamic-pituitary-adrenal (HPA) axis. Use in pediatric patients under 12 years of age is not recommended.

As with other highly active corticosteroids, therapy should be discontinued when control has been achieved. If no improvement is seen within 2 weeks, reassessment of the diagnosis may be necessary.


See all Temovate indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Temovate (Clobetasol Topical)

Improved treatment for dermatitis in cancer patients
Source: Cancer / Oncology News From Medical News Today [2014.12.11]
Researchers have shown how a topical steroid cream frequently used to treat common skin conditions, can be used to improve dermatitis in cancer patients.

Picture of Allergic Contact Dermatitis
Source: MedicineNet Allergic Cascade Specialty [2014.12.08]
Title: Picture of Allergic Contact Dermatitis
Category: Images
Created: 10/19/2009 12:18:00 PM
Last Editorial Review: 12/8/2014 12:00:00 AM

Seborrheic Dermatitis
Source: MedicineNet Seborrhea Specialty [2014.08.27]
Title: Seborrheic Dermatitis
Category: Diseases and Conditions
Created: 3/16/2012 5:47:00 PM
Last Editorial Review: 8/27/2014 12:00:00 AM

Atopic Dermatitis
Source: MedicineNet Otitis Externa Specialty [2014.04.23]
Title: Atopic Dermatitis
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 4/23/2014 12:00:00 AM

Atopic Eczema (Atopic Dermatitis) Quiz: Test Your Skin Disorders IQ
Source: MedicineNet pimecrolimus Specialty [2013.12.20]
Title: Atopic Eczema (Atopic Dermatitis) Quiz: Test Your Skin Disorders IQ
Category: MedicineNet Quiz
Created: 3/20/2012 12:50:00 PM
Last Editorial Review: 12/20/2013 12:24:14 PM

more news >>

Published Studies Related to Temovate (Clobetasol Topical)

Clobetasol propionate, 0.05%, vs hydrocortisone, 1%, for alopecia areata in children: a randomized clinical trial. [2014]
IMPORTANCE: Alopecia areata is an idiopathic cause of hair loss with limited therapeutic repertoire. OBJECTIVE: To compare the efficacy and safety of a high- vs low-potency topical corticosteroid in pediatric patients...

A comparative study in efficacy and safety of 0.1% tacrolimus and 0.05% clobetasol propionate ointment in discoid lupus erythematosus by modified cutaneous lupus erythematosus disease area and severity index. [2012]
CONCLUSION: The present study proved the efficacy of twice-daily tacrolimus and

A double-blind, randomized, placebo-controlled trial of topical tacrolimus 0.1% vs. clobetasol propionate 0.05% in childhood vitiligo. [2011.09]
BACKGROUND: Both clobetasol propionate 0.05% (CP 0.05%) and tacrolimus 0.1% (T 0.1%) ointments have been shown to be efficacious and safe in treating vitiligo in the paediatric population. OBJECTIVES: To assess efficacy and safety of these two therapies compared with each other and with placebo... CONCLUSIONS: Both CP 0.05% and T 0.1% ointments offer similar benefit in paediatric vitiligo, both facial and nonfacial. The facial lesions responded faster than the nonfacial ones. (c) 2011 The Authors. BJD (c) 2011 British Association of Dermatologists.

Clobetasol propionate 0.05% spray for the management of moderate-to-severe plaque psoriasis of the scalp: results from a randomized controlled trial. [2011.08]
BACKGROUND: Clobetasol propionate 0.05% spray is available for treating moderate-to-severe plaque psoriasis; however, there is limited information with plaque psoriasis of the scalp. OBJECTIVE: Evaluate the efficacy, safety, and quality-of-life impact of clobetasol propionate 0.05% spray in patients with moderate to severe plaque psoriasis of the scalp... CONCLUSION: Treatment with clobetasol propionate 0.05% spray for up to four weeks is effective and well tolerated for moderate-to-severe plaque psoriasis of the scalp.

Comparison of clobetasol propionate cream plus coal tar vs. topical psoralen and solar ultraviolet A therapy in palmoplantar psoriasis. [2011.08]
AIM: Palmoplantar psoriasis (PPP) produces significant morbidity and requires prompt treatment. Topical agents form the mainstay of therapy. We compared the efficacy and side-effect profile of a steroid/coal-tar combination with topical psoralen and solar ultraviolet A (PUVAsol) in PPP... CONCLUSION: Both treatments had comparable efficacy. In both groups, patients experienced 'good improvement' after 16 weeks of therapy. (c) The Author(s). CED (c) 2011 British Association of Dermatologists.

more studies >>

Clinical Trials Related to Temovate (Clobetasol Topical)

A Comparison Between Clobetasol Propionate 0.05% (Clobex®) Spray and Clobetasol Propionate 0.05% (Olux®) Foam [Completed]

Efficacy, Tolerance and Satisfaction With CLOBEX® Spray When Used as Monotherapy or Add-on Therapy in Plaque Psoriasis [Completed]
Evaluation of the effectiveness of Clobex® Spray, 0. 05% when used as monotherapy or add-on therapy to existing systemic or topical anti-psoriatic agents.

Interest of Topical Spironolactone's Administration to Prevent Corticoid-induced Epidermal Atrophy [Recruiting]
The purpose of this study is to determine whether spironolactone could significantly reduce cutaneous atrophy due to corticosteroids.

Efficacy, Safety, Preference and Response Duration of Clobex® Spray and Taclonex® Ointment in Psoriasis [Completed]

Maintenance Effect of Clobex Shampoo on Subjects With Moderate to Severe Scalp Psoriasis [Completed]
The objective of the study is to assess the maintenance effect on scalp psoriasis of Clobex® Shampoo 0. 05% when used twice weekly.

more trials >>


PATIENT REVIEWS / RATINGS / COMMENTS

Based on a total of 2 ratings/reviews, Temovate has an overall score of 7. The effectiveness score is 6 and the side effect score is 10. The scores are on ten point scale: 10 - best, 1 - worst.
 

Temovate review by 46 year old female patient

  Rating
Overall rating:  
Effectiveness:   Moderately Effective
Side effects:   No Side Effects
  
Treatment Info
Condition / reason:   dyshidrosis
Dosage & duration:   twice daily (dosage frequency: twice daily) for the period of two weeks
Other conditions:   noce
Other drugs taken:   None
  
Reported Results
Benefits:   The resulting small, fluid-filled blisters (vesicles) most commonly occur on the palms and fingers of your hands and on the soles and toes of your feet. The blisters usually last for three to four weeks. The blisters often cause intense itching. Scratching the blisters can damage the skin and, in some cases, lead to infection. Once the blisters dry, they often leave cracks and painful grooves (fissures) in your skin. Risk factors Dyshidrosis occurs twice as often in women as in men. Other risk factors include: * Stress, because dyshidrosis appears to be more common during times of stress * Exposure to metal salts, such as chromium, cobalt and nickel — usually through cement or mechanical work * Having seasonal allergies, such as hay fever * Frequently exposing your skin to water or other wet substances
Side effects:   The resulting small, fluid-filled blisters (vesicles) most commonly occur on the palms and fingers of your hands and on the soles and toes of your feet. The blisters usually last for three to four weeks. The blisters often cause intense itching. Scratching the blisters can damage the skin and, in some cases, lead to infection. Once the blisters dry, they often leave cracks and painful grooves (fissures) in your skin. Risk factors Dyshidrosis occurs twice as often in women as in men. Other risk factors include: * Stress, because dyshidrosis appears to be more common during times of stress * Exposure to metal salts, such as chromium, cobalt and nickel — usually through cement or mechanical work * Having seasonal allergies, such as hay fever * Frequently exposing your skin to water or other wet substances
Comments:   The resulting small, fluid-filled blisters (vesicles) most commonly occur on the palms and fingers of your hands and on the soles and toes of your feet. The blisters usually last for three to four weeks. The blisters often cause intense itching. Scratching the blisters can damage the skin and, in some cases, lead to infection. Once the blisters dry, they often leave cracks and painful grooves (fissures) in your skin. Risk factors Dyshidrosis occurs twice as often in women as in men. Other risk factors include: * Stress, because dyshidrosis appears to be more common during times of stress * Exposure to metal salts, such as chromium, cobalt and nickel — usually through cement or mechanical work * Having seasonal allergies, such as hay fever * Frequently exposing your skin to water or other wet substances

 

Temovate review by 49 year old male patient

  Rating
Overall rating:  
Effectiveness:   Moderately Effective
Side effects:   No Side Effects
  
Treatment Info
Condition / reason:   Dyshidrosis
Dosage & duration:   0.05% (dosage frequency: 2x per day) for the period of 2 weeks
Other conditions:   None
Other drugs taken:   None
  
Reported Results
Benefits:   reduced symptoms after using the cream for a total of two months.
Side effects:   There were no apparent side effect from using this treatment.
Comments:   cream applied twice per day for two weeks. one week without treatment and than two weeks on the treatment. Repeat this regiment until symptoms are reduced or disappear.

See all Temovate reviews / ratings >>

Page last updated: 2014-12-11

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014